Published in Am J Clin Oncol on April 01, 2012
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol (2010) 5.99
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Variability and memory of protein levels in human cells. Nature (2006) 6.15
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Management of non-small-cell lung cancer: recent developments. Lancet (2013) 3.51
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.40
Proteome half-life dynamics in living human cells. Science (2011) 3.34
Dynamic proteomics in individual human cells uncovers widespread cell-cycle dependence of nuclear proteins. Nat Methods (2006) 2.94
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J (2004) 2.85
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res (2006) 2.84
Relation between randomized controlled trials published in leading general medical journals and the global burden of disease. CMAJ (2004) 2.83
HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol (2013) 2.78
Surgical or medical treatment for thrombus straddling the patent foramen ovale: impending paradoxical embolism? Report of four clinical cases and literature review. Arch Cardiovasc Dis (2008) 2.76
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis (2013) 2.71
Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation (2005) 2.69
The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.64
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA (2004) 2.47
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol (2013) 2.44
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. Mol Cell (2007) 2.20
Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol (2006) 2.19
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res (2010) 2.12
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res (2012) 1.95
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys (2007) 1.83
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. J Thorac Oncol (2009) 1.72
Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol (2013) 1.71
Endocarditis in the elderly: clinical, echocardiographic, and prognostic features. Eur Heart J (2003) 1.71
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol (2010) 1.68
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer Discov (2012) 1.63
Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy. Am J Cardiol (2008) 1.59
Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res (2007) 1.59
Comparison of sulfur hexafluoride microbubble (SonoVue)-enhanced myocardial contrast echocardiography with gated single-photon emission computed tomography for detection of significant coronary artery disease: a large European multicenter study. J Am Coll Cardiol (2013) 1.58
Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol (2004) 1.58
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol (2010) 1.52
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol (2006) 1.51
RESICARD: East Paris network for the management of heart failure: absence of effect on mortality and rehospitalization in patients with severe heart failure admitted following severe decompensation. Arch Cardiovasc Dis (2009) 1.49
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol (2011) 1.48
Involvement of aquaporins in colorectal carcinogenesis. Oncogene (2003) 1.45
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer (2009) 1.45
Telomerase expression in lung preneoplasia and neoplasia. Int J Cancer (2007) 1.45
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
Frequency of drug-induced valvular heart disease in patients previously exposd to benfluorex: a multicentre prospective study. Eur Heart J (2013) 1.42
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer (2012) 1.40
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res (2012) 1.39
Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie (2012) 1.39
Generation of a fluorescently labeled endogenous protein library in living human cells. Nat Protoc (2007) 1.36
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol (2010) 1.36
Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol (2007) 1.34
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol (2012) 1.33
Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol (2009) 1.32
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
[European National Society cardiovascular journals. Background, rationale and mission statement of the "editors' club"]. Rev Esp Cardiol (2008) 1.26
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol (2004) 1.25
ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med (2007) 1.24
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol (2012) 1.23
ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer (2012) 1.22
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Invest New Drugs (2009) 1.20
Sequential therapy in renal cell carcinoma. Cancer (2009) 1.18
Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models. Crit Rev Oncol Hematol (2012) 1.18
ERCC1 and RRM1: ready for prime time? J Clin Oncol (2013) 1.17
Aquaporin expression in human lymphocytes and dendritic cells. Am J Hematol (2004) 1.17
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol (2009) 1.15
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
Tumor assessment criteria in phase I trials: beyond RECIST. J Clin Oncol (2012) 1.15
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol (2011) 1.14
Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process. Crit Rev Oncol Hematol (2008) 1.12
Cisplatin resistance associated with PARP hyperactivation. Cancer Res (2013) 1.11
Inclusion of patients with advanced cancer in phase I trials: is this a tool for improving optimism and emotional well-being? J Clin Oncol (2013) 1.08
Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clin Cancer Res (2011) 1.08
Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol Hematol (2012) 1.06
Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res (2013) 1.05
Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res (2007) 1.05
Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol (2012) 1.04
Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol (2007) 1.04
hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin Cancer Res (2002) 1.04
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol (2010) 1.04
NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol (2005) 1.01
Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer (2013) 1.01
Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer (2011) 1.00
Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology (2012) 1.00
Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer (2004) 1.00
Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer (2011) 1.00